Skip to main content

Table 3 Response to therapy by tumor type

From: Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose

Tumor type

N

PD

SD

PR

Soft tissue sarcoma

7

2

5

 

AGASACA

7

 

7

 

Thyroid carcinoma

7

 

5

2

Nasal carcinoma

5

2

3

 

Squamous cell carcinoma

4

 

2

2

Metastatic osteosarcoma (lung)

3

 

3

 

Primary pulmonary carcinoma

3

 

3

 

Billiary carcinoma

1

 

1

 

Poorly differentiated carcinoma

1

 

1

 

Salivary gland adenocarcinoma

1

  

1

Mediastinal carcinoma

1

 

1

 

Total

40

4

31

 
  1. PD Progressive Disease SD, Stable disease PR Partial response.